Connecticut 2021 Regular Session

Connecticut Senate Bill SB00269

Introduced
1/22/21  
Introduced
1/22/21  
Refer
1/22/21  
Refer
1/22/21  
Report Pass
2/16/21  
Report Pass
2/16/21  
Refer
2/26/21  
Refer
2/26/21  
Report Pass
3/4/21  

Caption

An Act Concerning The Availability Of Generic Pharmaceuticals.

Companion Bills

No companion bills found.

Previously Filed As

CT SB00008

An Act Concerning Drug Affordability.

CT SB00212

An Act Concerning The Revisor's Technical Corrections To The General Statutes.

CT HB05145

An Act Concerning Innovation Banks.

CT HB05150

An Act Concerning Cannabis And Hemp Regulation.

CT SB00401

An Act Concerning The Availability Of Telehealth Providers In Determining Network Adequacy And Extending The Telehealth Provisions Adopted During The Covid-19 Pandemic.

CT HB05235

An Act Concerning The Department Of Consumer Protection's Recommendations Regarding Cannabis Regulation.

CT HB05236

An Act Concerning Recommendations By The Department Of Consumer Protection.

CT SB00398

An Act Concerning The Regulation And Taxation Of Travel Insurance And Associated Entities, Products And Professionals.

CT SB00201

An Act Concerning Unfair Real Estate Listing Agreements And The Connecticut Unfair Trade Practices Act.

CT HB05523

An Act Concerning Allocations Of Federal American Rescue Plan Act Funds And Provisions Related To General Government, Human Services, Education And The Biennium Ending June 30, 2025.

Similar Bills

CA AB824

Business: preserving access to affordable drugs.

CT HB06619

An Act Concerning Prohibiting Pay For Delay.

CT SB00251

An Act Concerning The Availability Of Generic Pharmaceuticals.

NY A08576

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

RI H5913

Provides that an agreement resolving a patent infringement claim, in connection with the sale of a pharmaceutical product, is to be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value.

CA SB1508

Corporate taxation: voluntary disclosure agreements: qualified entities.

CA SB1399

Transfer of real property: transfer fees.

CA SB512

Public postsecondary education: support services for foster youth: Cooperating Agencies Foster Youth Educational Support Program.